NCT03893526

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

The Effect of Neprilysin on Plasma Concentrations of Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University of Copenhagen · Academic / Other
• Sex: Male
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the degradation of GLP-1 but if this is the case in humans with type 2 diabetes is unknown. We therefore administered a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin 100mg the night before and 100mg 2 hours before), both, or placebo, to patients with type 2 diabetes during a standardized meal and measured plasma concentrations of GLP-1

Conditions

• Type2 Diabetes

Interventions

Type	Name	Description
DRUG	Entresto	Single dose administration of entresto
DRUG	Sitagliptin	Single dose administration of sitagliptin
DRUG	Valsartan	single doses administration of valsartan
DRUG	Placebo	placebo day

Timeline

• Start date: 2019-01-25
• Primary completion: 2021-03-01
• Completion: 2021-03-01
• First posted: 2019-03-28
• Last updated: 2021-05-05

Locations

1 site across 1 country: Denmark